TMCnet News

Research and Markets: Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles
[September 12, 2014]

Research and Markets: Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/bcj3rn/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

The report enhances decisionmaking capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Companies Involved in Therapeutics Development

  • Johnson & Johnson
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AbGenomics International, Inc.
  • ApoPharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • OPKO Health, Inc.
  • Idera Pharmaceuticals, Inc.
  • Almirall, S.A.
  • Syntrix Biosystems, Inc.
  • Vascular Biogenics Ltd.
  • Hy BioPharma Inc.
  • GlycoMar Limited
  • Convoy Therapeutics, Inc.

Drug Profiles


  • brodalumab
  • ixekizumab
  • secukinumab
  • tildrakizumab
  • LAS-41008
  • adalimumab biosimilar
  • baricitinib
  • AbGn-168H
  • VB-201
  • lunacalcipol
  • aminopterin sodium
  • HBP-347
  • orilotimod
  • BI-655066
  • IMO-8400
  • PF-04965842
  • MOL-4249
  • AVX (News - Alert)-001
  • AMG-811
  • guselkumab
  • AKP-11
  • cyclosporine
  • GLY-2028

For more information visit http://www.researchandmarkets.com/research/bcj3rn/moderate


[ Back To TMCnet.com's Homepage ]